BRCA1 vs. BRCA2: Key Cancer Risk Differences

01 / 09

Two separate genes in the same repair pathway

BRCA1 and BRCA2 are distinct tumor-suppressor genes. Both help repair damaged DNA, but they sit at different locations and inherited pathogenic variants produce different patterns of cancer risk.

BRCA1

17q21.31

DNA repair associated; NCBI Gene ID 672. ^[2,4]

BRCA2

13q13.1

DNA repair associated; NCBI Gene ID 675. ^[3,5]

Everyone has both genes. The comparison below concerns inherited pathogenic or likely pathogenic variants—not the genes themselves and not variants of uncertain significance. For a broader foundation, read the BRCA1 and BRCA2 overview.

02 / 09

How the cancer risks compare

BRCA1 generally carries the higher ovarian cancer range. BRCA2 is more strongly associated with male breast cancer and carries higher reported prostate and pancreatic cancer ranges.

These are cumulative estimates for people with a pathogenic variant. They are population ranges—not personal forecasts—and vary with age, sex, family history, ancestry, study design, and the specific variant. ^[1,6]

Cancer risk ranges for people with pathogenic BRCA1 or BRCA2 variants.
Cancer risk	BRCA1	BRCA2	Comparison
Female breast, lifetime	55–72%	45–69%	Ranges overlap substantially. ^[1]
Ovarian, lifetime	39–58%	13–29%	Higher range with BRCA1. ^[1]
Prostate, by age 80	7–26%	19–61%	Higher range with BRCA2. ^[1]
Pancreatic, lifetime	Up to 5%	5–10%	Higher range with BRCA2. ^[1]
Male breast	Increased association	Stronger association	BRCA2 is more strongly associated; no single estimate applies to everyone. ^[1,6]

Female breast, ovarian, and pancreatic figures are lifetime estimates; prostate estimates are through age 80. Comparing studies requires checking the population and age horizon.

03 / 09

Tumor profiles are different, too

BRCA1-associated breast cancers are more often triple-negative. BRCA2-associated breast cancers are more often hormone-receptor-positive.

More common association

BRCA1 → triple-negative

Tumors lack estrogen receptor, progesterone receptor, and HER2 expression more often than sporadic breast cancers.

More common association

BRCA2 → hormone-receptor-positive

Tumors more often express estrogen and/or progesterone receptors than BRCA1-associated tumors.

These are general pathology associations, not rules for every tumor and not treatment advice. Receptor testing, stage, the person’s health, and other tumor findings guide care. ^[7]

04 / 09

Inheritance is the same for both genes

50%

Hereditary cancer susceptibility from one pathogenic BRCA1 or BRCA2 variant follows an autosomal dominant pattern. Each child of a carrier has a 50% chance of inheriting that variant, independently for each pregnancy. People of any sex can inherit and pass on either variant. ^[1,6]

05 / 09

Can the same test analyze BRCA1 and BRCA2?

Yes. Clinical hereditary cancer panels and whole-genome sequencing can analyze both genes. But “includes BRCA1 and BRCA2” does not mean every test has the same coverage, methods, or reporting policy.

Strengths and limits of common approaches to BRCA testing.
Testing approach	What it asks	Key consideration
Known-family-variant test	Did I inherit the exact variant found in my relative?	Often the best first test when that variant is documented.
Hereditary cancer panel	Are relevant variants present in BRCA1/2 and selected additional cancer genes?	Gene list, variant classes, deletion/duplication analysis, and reporting vary.
Whole-genome sequencing	What inherited findings are present across a much broader genome-wide dataset?	Coverage, validated variant classes, interpretation, confirmation, and reportable findings vary.
Founder-variant report	Are selected variants common in a particular ancestry group present?	A negative result can miss other pathogenic variants in both genes.

Before testing, ask which genes, regions, and variant types are assessed; whether findings are clinically confirmed; and what happens when a variant of uncertain significance is found. ^[6,8,9]

06 / 09

A broader view of inherited risk

A narrow founder or single-gene test sees only what it was built to check. Whole-genome sequencing creates a broader data foundation that can support analysis across BRCA1, BRCA2, and many other genes.

Where HLI fits

Approximately 30× whole-genome sequencing for $599, with a genome-wide data foundation and analysis extending beyond one hereditary cancer question.

HLI’s service includes a cancer risk assessment covering BRCA1/2 among other genes, plus cardiovascular and pharmacogenomic findings. This can provide a more comprehensive picture of inherited cancer risk across many genes than a narrow test—but broader does not mean definitive.

See what the $599 genome service includes

Important limits

WGS is not guaranteed to detect or report every clinically relevant variant. Findings may require clinical confirmation and genetic counseling. If a familial variant is already known, targeted clinical testing for that variant can be the best first test. A negative result does not erase risk suggested by personal or family history. ^[6,8]

07 / 09

Choose the next step around the question

01
Start with the family record
Document cancer types, ages at diagnosis, ancestry, and any relatives’ genetic reports from both sides of the family.
02
Test an affected relative first when possible
A result from someone who has had a related cancer can make testing in relatives more informative.
03
Match the test to the evidence
Use targeted testing for a known familial variant; consider a clinical panel or broader sequencing when the cause is unknown.
04
Interpret before acting
Discuss positive, negative, and uncertain findings with a genetics professional before changing screening or preventive care.

Learn who should consider BRCA testing, understand what BRCA results mean, or review HLI’s whole-genome service.

08 / 09

Frequently asked questions

Q1Is BRCA1 or BRCA2 worse?

Neither gene is universally “worse.” BRCA1 is associated with higher ovarian cancer risk and breast tumors that are more often triple-negative. BRCA2 is associated with higher prostate, pancreatic, and male breast cancer risk. Personal risk also depends on age, sex, family history, the specific variant, and other factors. ^[1,6,7]

Q2Can one test check both BRCA1 and BRCA2?

Yes. Many clinical hereditary cancer panels and whole-genome sequencing services can analyze both genes. The regions assessed, variant classes detected, validation, and findings reported vary by laboratory and service, so the test specification matters. ^[6,8]

Q3Does a negative direct-to-consumer BRCA result rule out inherited risk?

No. Some direct-to-consumer or founder-variant reports check only a small set of variants. A negative limited report does not exclude other pathogenic BRCA1 or BRCA2 variants or inherited risk in other cancer genes. ^[1,9]

Q4When is targeted testing better than whole-genome sequencing?

When a pathogenic familial variant is already known, a targeted clinical test for that exact variant can be the clearest and most efficient first test. A genetics professional can determine whether additional panel or broader testing is also appropriate. ^[6,8]

09 / 09

References and review notes

Sources and service context were reviewed September 28, 2026. Risk estimates, clinical guidance, and service scope can change.